Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
3.4
Journals
Vaccines
Special Issues
Vaccination for Patients with Hematologic Diseases
share announcement

Vaccination for Patients with Hematologic Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 949

Special Issue Editor

Dr. Monia Marchetti

E-Mail Website
Guest Editor
Hematology Department, University Hospital SS Antonio e Biagio & Cesare Arrigo, Alessandria, Italy
Interests: chronic myeloproliferative neoplasms; immune thrombocytopenia; evidence-based medicine; artificial intelligence; decision analysis; health technology assessment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Patients with blood disorders often demonstrate a suboptimal response to viral and bacterial infections. Therefore, active or passive immune prophylaxis is essential in specific subgroups to improve infection outcomes. The most effective strategy for preventing adverse outcomes related to infections depends on various factors, including host-related, disease-related, therapy-related, and context-related considerations, as well as the availability of specific vaccines. We are pleased to invite you to contribute to this Special Issue, which will focus on active and passive immune prophylaxis in patients with blood malignancies or non-neoplastic blood disorders.

This Special Issue will explore strategies to selectively enhance patients' immune responses to specific infections and the broad clinical implications of effective prevention in those undergoing complex treatment sequences. Original research articles and reviews are welcome. Areas of interest include the management of vaccination in patients eligible for CAR T-cell therapies, the current management of active and passive immune prophylaxis for SARS-CoV-2, and newly introduced RSV vaccines.

Thank you for considering this opportunity to share your insights and research.

Dr. Monia Marchetti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • SARS-CoV-2
  • influenza
  • leukemia
  • lymphoma
  • myeloma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 541 KB  
Article
Key Indications for Passive Immune Prophylaxis Against SARS-CoV-2 Infection in Malignant Hematological Disorders: An Analytic Hierarchy Process by an Ad Hoc Italian Expert Panel
by Monia Marchetti, Giovanni Barosi, Francesco Passamonti, Marco Falcone, Emanuele Nicastri, Simona Sica, Pellegrino Musto, Francesca Romana Mauro and Corrado Girmenia
Vaccines 2026, 14(1), 46; https://doi.org/10.3390/vaccines14010046 - 30 Dec 2025
Viewed by 672
Abstract
Background: Pre-exposure passive immune prophylaxis (PrEP) might contribute to improve hematologic malignancy (HM) outcomes; however, there are currently no specific guidelines to inform patient selection. Methods: A literature review and a Delphi consensus process were used to identify COVID-19 risk factors, critical COVID-19 [...] Read more.
Background: Pre-exposure passive immune prophylaxis (PrEP) might contribute to improve hematologic malignancy (HM) outcomes; however, there are currently no specific guidelines to inform patient selection. Methods: A literature review and a Delphi consensus process were used to identify COVID-19 risk factors, critical COVID-19 outcomes, and efficacy of PrEP against SARS-CoV-2 in HMs. An analytic hierarchy process was used to assign a priority score to candidate outcomes and to determine the PrEP indications. For these decisions, the experts assumed adequate compliance with anti-COVID-19 vaccination and acknowledged the effectiveness of PrEP in reducing SARS-CoV-2-related mortality and hospital admissions. Results: Based on the literature review, the expert panel identified 80 risk categories among patients with HM and prioritized eight clinical outcomes related to SARS-CoV-2 PrEP. The highest mean priority scores were observed for HM-related mortality (7.0), intensive care unit admission (6.7), and delays in anti-HM treatment (6.6). Based on such a framework, the experts deemed that if there was a variant-specific PrEP promptly available, it would be considered mandatory for all candidates receiving allogeneic hematopoietic cell transplantation, CAR-T therapy, or bispecific antibodies, regardless of local viral epidemiology. During epidemiological waves, variant-specific PrEP would also be recommended for patients with HMs at high risk of unfavorable COVID-19 clinical outcomes. Conclusions: This study identified PrEP indications for patients with HM receiving appropriate active immunization against COVID-19. Full article
(This article belongs to the Special Issue Vaccination for Patients with Hematologic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop